Anti-neuroinflammatory Drug Development
Anti-neuroinflammatory drugs are a class of medications that seek to treat inflammation of the central nervous system (CNS). Protheragen claims to have a highly regarded group of researchers and scientists who are well known for their work involving anti neuroinflammatory drugs. They are determined to lead meaningful change by delivering advanced anti-neuroinflammatory treatment innovations to areas of unmet therapeutic need to drive change in the shifting landscape of medicine.
Introduction to Anti-neuroinflammatory Drugs
Anti-neuroinflammatory drugs refers to a group of therapeutic agents that focus on the treatment of chronic inflammation specific to neurological diseases. Their mechanisms of action differs from those of peripheral anti-inflammatory drugs. These drugs modify at least some aspects of microglial activation, astrocytic reactivity, and neuroimmune signaling integrated in the pathology of neurological diseases. Strategies include the development of microglia polarizing agents, cytokine blockers, and compounds inhibiting inflammasomes meant to cross the blood-brain barrier and minimize systemic immunosuppression.
Fig.1 Numerous stimuli such as Aβ peptides, neurotoxin and proinflammatory mediators activates microglial cells and astrocytes. (Shal B, et al., 2018)
Mechanisms of Action of Anti-neuroinflammatory Drugs
Microglial Modulation
Anti-neuroinflammatory drugs target microglial activation states through receptors like TREM2 and CSF1R, shifting pro-inflammatory M1 phenotypes toward neuroprotective M2 states.
Cytokine Signaling Interruption
Drugs precisely neutralize neurotoxic cytokines like IL-1β and IL-6, demonstrating 30-50% reductions in neuronal damage across neurodegenerative models.
Astrocyte Regulation
These therapeutics correct reactive astrogliosis by blocking inflammatory pathways in A1 astrocytes, particularly through LRRK2 inhibition and connexin-43 modulation to prevent inflammatory spread.
Complement System Inhibition
Complement blockers optimized for the central nervous system (CNS), such as C1q inhibitors and C3aR antagonists, can protect synapses and neuromuscular junctions.
Development of Anti-neuroinflammatory Drugs
| Drug Names | Indications | Targets | Mechanism of Action | Phase |
| ANX005 | Amyotrophic lateral sclerosis (ALS) | C1q | Inhibits complement-mediated synapse loss | Phase II |
| Ibudilast | Multiple sclerosis (MS), ALS | PDE4/10 | Suppresses microglial activation and neuroinflammation | Phase II |
| Fingolimod | Huntington's disease | S1P receptor | Reduces CNS lymphocyte infiltration | Approved |
| XPro1595 | Alzheimer's disease | Soluble TNF | Neutralizes soluble TNF without affecting transmembrane TNF | Phase II |
| MCC950 | Parkinson's disease, Alzheimer's disease | NLRP3 inflammasome | Blocks IL-1β and IL-18 maturation | Phase I |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Committed to advancing the treatment of rare neurological disorders, Protheragen offers comprehensive anti-neuroinflammatory drug development services, integrating target validation, lead compound optimization, and predictive preclinical testing based on patient-derived cell models and transgenic systems. Our end-to-end platform utilizes disease-relevant models, blood-brain barrier penetration design algorithms, and GLP-compliant neurotoxicity assessments to develop neuroprotective drug candidates with proven efficacy and safety.
Anti-neuroinflammatory Drug Development Platforms
Targets of Anti-neuroinflammatory Drug Development
Focusing on developing anti-neuroinflammatory drugs against multiple targets, our mission is to effectively combat neuroinflammation in rare neurological diseases and revolutionize the treatment landscape.
- TREM2
- CSF1R
- P2X7R
- NLRP3
- AIM2
- IL-1β
- TNF-α
- CCL2 (MCP-1)
- C1q
- C3aR/C5aR
- S1P receptors
- mGluR5
- PDE4/PDE10
- IDO1
- TRPM2
- Kv1.3
- NF-κB
- NRF2
- JAK/STAT
- More
Protheragen provides integrated pharmacodynamic (PD), pharmacokinetic (PK), and neurotoxicity profiling services specifically tailored for anti-neuroinflammatory drug candidates, featuring microglial activation assays, CNS penetration studies, and neurobehavioral safety assessments. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Shal B, Ding W, Ali H, et al. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer's disease[J]. Frontiers in pharmacology, 2018, 9: 548.